Tag:
TC-5619
Latest Headlines
Latest Headlines
In fresh setback, Targacept drug flunks PhII ADHD study
Just three weeks after reporting that GlaxoSmithKline was dumping its big neuroscience drug development pact , Targacept says one of its other treatments flunked a proof-of-concept study for ADHD.
Targacept schizophrenia drug meets Phase II goal
Targacept could be in line for a $30 million payment if AstraZeneca chooses to license its mid-stage drug for schizophrenia. In a Phase II trial, TC-5619 met the protocol met the main endpoint of the
